Literature DB >> 29581235

Myeloperoxidase-derived oxidants damage artery wall proteins in an animal model of chronic kidney disease-accelerated atherosclerosis.

Lixia Zeng1, Anna V Mathew1, Jaeman Byun1, Kevin B Atkins1, Frank C Brosius2, Subramaniam Pennathur3.   

Abstract

Increased myeloperoxidase (MPO) levels and activity are associated with increased cardiovascular risk among individuals with chronic kidney disease (CKD). However, a lack of good animal models for examining the presence and catalytic activity of MPO in vascular lesions has impeded mechanistic studies into CKD-associated cardiovascular diseases. Here, we show for the first time that exaggerated atherosclerosis in a pathophysiologically relevant CKD mouse model is associated with increased macrophage-derived MPO activity. Male 7-week-old LDL receptor-deficient mice underwent sham (control mice) or 5/6 nephrectomy and were fed either a low-fat or high-fat, high-cholesterol diet for 24 weeks, and the extents of atherosclerosis and vascular reactivity were assessed. MPO expression and oxidation products-protein-bound oxidized tyrosine moieties 3-chlorotyrosine, 3-nitrotyrosine, and o,o'-dityrosine-were examined with immunoassays and confirmed with mass spectrometry (MS). As anticipated, the CKD mice had significantly higher plasma creatinine, urea nitrogen, and intact parathyroid hormone along with lower hematocrit and body weight. On both the diet regimens, CKD mice did not have hypertension but had lower cholesterol and triglyceride levels than the control mice. Despite the lower cholesterol levels, CKD mice had increased aortic plaque areas, fibrosis, and luminal narrowing. They also exhibited increased MPO expression and activity (i.e. increased oxidized tyrosines) that co-localized with infiltrating lesional macrophages and diminished vascular reactivity. In summary, unlike non-CKD mouse models of atherosclerosis, CKD mice exhibit increased MPO expression and catalytic activity in atherosclerotic lesions, which co-localize with lesional macrophages. These results implicate macrophage-derived MPO in CKD-accelerated atherosclerosis.
© 2018 by The American Society for Biochemistry and Molecular Biology, Inc.

Entities:  

Keywords:  3-chlorotyrosine; 3-nitrotyrosine; Chronic Kidney Disease; atherosclerosis; macrophage; mass spectrometry (MS); myeloperoxidase; oxidative stress; oxidized amino acids

Mesh:

Substances:

Year:  2018        PMID: 29581235      PMCID: PMC5949994          DOI: 10.1074/jbc.RA117.000559

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  97 in total

1.  Transgenic mice express human MPO -463G/A alleles at atherosclerotic lesions, developing hyperlipidemia and obesity in -463G males.

Authors:  Lawrence W Castellani; James J Chang; Xuping Wang; Aldons J Lusis; Wanda F Reynolds
Journal:  J Lipid Res       Date:  2006-04-25       Impact factor: 5.922

2.  Prognostic value of myeloperoxidase in patients with chest pain.

Authors:  William E Cayley
Journal:  N Engl J Med       Date:  2004-01-29       Impact factor: 91.245

3.  Statins promote potent systemic antioxidant effects through specific inflammatory pathways.

Authors:  Mehdi H Shishehbor; Marie-Luise Brennan; Ronnier J Aviles; Xiaoming Fu; Marc S Penn; Dennis L Sprecher; Stanley L Hazen
Journal:  Circulation       Date:  2003-07-14       Impact factor: 29.690

Review 4.  Koch's postulates for cholesterol.

Authors:  M S Brown; J L Goldstein
Journal:  Cell       Date:  1992-10-16       Impact factor: 41.582

Review 5.  Role of oxidized low density lipoprotein in atherogenesis.

Authors:  J L Witztum; D Steinberg
Journal:  J Clin Invest       Date:  1991-12       Impact factor: 14.808

Review 6.  Carbamylation-derived products: bioactive compounds and potential biomarkers in chronic renal failure and atherosclerosis.

Authors:  Stéphane Jaisson; Christine Pietrement; Philippe Gillery
Journal:  Clin Chem       Date:  2011-07-18       Impact factor: 8.327

7.  Cardiovascular disease risk factors in chronic renal insufficiency.

Authors:  M J Sarnak; B E Coronado; T Greene; S R Wang; J W Kusek; G J Beck; A S Levey
Journal:  Clin Nephrol       Date:  2002-05       Impact factor: 0.975

8.  Atherosclerotic cardiovascular disease risks in chronic hemodialysis patients.

Authors:  A K Cheung; M J Sarnak; G Yan; J T Dwyer; R J Heyka; M V Rocco; B P Teehan; A S Levey
Journal:  Kidney Int       Date:  2000-07       Impact factor: 10.612

9.  Associations between the CYBA 242C/T and the MPO -463G/A polymorphisms, oxidative stress and cardiovascular disease in chronic kidney disease patients.

Authors:  Debora A Grahl; Jonas Axelsson; Louise Nordfors; Olof Heimburger; Peter Bárány; Yuan-Zhe Gao; Abdul Rashid Qureshi; Sawako Kato; Makoto Watanabe; Mohamed Suliman; Miguel C Riella; Bengt Lindholm; Peter Stenvinkel; Roberto Pecoits-Filho
Journal:  Blood Purif       Date:  2007       Impact factor: 2.614

10.  The role of myeloperoxidase in the microbicidal activity of polymorphonuclear leukocytes.

Authors:  S J Klebanoff; H Rosen
Journal:  Ciba Found Symp       Date:  1978 Jun 6-8
View more
  7 in total

1.  Anti-atherosclerotic Effects of Myrtenal in High-Fat Diet-Induced Atherosclerosis in Rats.

Authors:  Liyan Yu; Hongguang Liu; Xiaoxia Ma; Vidya Devanathadesikan Seshadri; Xuan Gao
Journal:  Appl Biochem Biotechnol       Date:  2022-07-09       Impact factor: 2.926

2.  Reactive Dicarbonyl Scavenging Effectively Reduces MPO-Mediated Oxidation of HDL and Restores PON1 Activity.

Authors:  Jiansheng Huang; Patricia G Yancey; Huan Tao; Mark S Borja; Loren E Smith; Valentina Kon; Sean S Davies; MacRae F Linton
Journal:  Nutrients       Date:  2020-06-30       Impact factor: 5.717

3.  Myeloperoxidase inhibition in mice alters atherosclerotic lesion composition.

Authors:  Rachel J Roth Flach; Chunyan Su; Eliza Bollinger; Christian Cortes; Andrew W Robertson; Alan C Opsahl; Timothy M Coskran; Kevin P Maresca; Edmund J Keliher; Phillip D Yates; Albert M Kim; Amit S Kalgutkar; Leonard Buckbinder
Journal:  PLoS One       Date:  2019-03-19       Impact factor: 3.240

4.  Myeloperoxidase Deficiency Inhibits Cognitive Decline in the 5XFAD Mouse Model of Alzheimer's Disease.

Authors:  Rotem Volkman; Tali Ben-Zur; Anat Kahana; Ben Zion Garty; Daniel Offen
Journal:  Front Neurosci       Date:  2019-09-24       Impact factor: 4.677

5.  Refining the Mouse Subtotal Nephrectomy in Male 129S2/SV Mice for Consistent Modeling of Progressive Kidney Disease With Renal Inflammation and Cardiac Dysfunction.

Authors:  James O'Sullivan; Sarah Louise Finnie; Oliver Teenan; Carolynn Cairns; Andrew Boyd; Matthew A Bailey; Adrian Thomson; Jeremy Hughes; Cécile Bénézech; Bryan Ronald Conway; Laura Denby
Journal:  Front Physiol       Date:  2019-11-15       Impact factor: 4.566

6.  Deletion of bone marrow myeloperoxidase attenuates chronic kidney disease accelerated atherosclerosis.

Authors:  Anna V Mathew; Lixia Zeng; Kevin B Atkins; Kiana N Sadri; Jaeman Byun; Hideaki Fujiwara; Pavan Reddy; Subramaniam Pennathur
Journal:  J Biol Chem       Date:  2020-12-03       Impact factor: 5.157

Review 7.  Myeloid leukocytes' diverse effects on cardiovascular and systemic inflammation in chronic kidney disease.

Authors:  Alexander Hof; Simon Geißen; Kezia Singgih; Martin Mollenhauer; Holger Winkels; Thomas Benzing; Stephan Baldus; Friedrich Felix Hoyer
Journal:  Basic Res Cardiol       Date:  2022-07-27       Impact factor: 12.416

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.